We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Read MoreHide Full Article
Key Takeaways
Halozyme shares fell 2.9% after a German court overturned the preliminary injunction against Keytruda SC.
HALO disagrees with the ruling and is seeking permanent relief through a new patent infringement lawsuit.
HALO's MDASE patent enforcement proceedings are separate from its ENHANZE licensing program.
Halozyme Therapeutics (HALO - Free Report) announced that a German Higher Regional Court has overturned a preliminary injunction that had prohibited Merck (MRK - Free Report) from distributing and offering Keytruda’s subcutaneous (SC) formulation in Germany.
The latest development follows a December 2025 ruling by a German court that granted Halozyme a preliminary injunction against Merck, preventing the distribution and offering of Keytruda SC in Germany. However, the Higher Regional Court has now overturned that order.
Halozyme expressed disappointment with the latest decision, stating that it disagrees with the court's ruling. The company plans to immediately file a patent infringement lawsuit against Merck in Germany, seeking permanent relief. The latest decision does not prevent Halozyme from pursuing further legal action.
Shares of Halozyme were down 2.9% yesterday following the announcement of the news.
The stock has rallied 38.3% so far this year compared with the industry’s increase of 5.7%.
Image Source: Zacks Investment Research
HALO’s Previous Court Ruling
In October 2026, a Dutch patent court ruled in Halozyme's favor in another patent dispute involving Merck's Keytruda SC. The court prohibited Merck's European Marketing Authorization holder from manufacturing, offering, selling or using Keytruda SC in eight European countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
It also prevents Merck from allowing its affiliates to continue selling the drug in these markets, including through the use of its European marketing authorization.
Importantly, the German and Dutch proceedings are separate and independent. Therefore, the latest German ruling does not reverse the Dutch court's October 2026 decision.
What This Means for Halozyme
The legal dispute centers on Halozyme's MDASE patent portfolio, which covers technology designed to facilitate the rapid subcutaneous administration of therapeutic drugs using modified human hyaluronidases.
Halozyme noted that its MDASE patents are separate from its ENHANZE drug delivery technology patents and are not included in its ENHANZE licensing program. Consequently, the outcome of the MDASE patent enforcement proceedings against Merck is not expected to affect the company's ENHANZE licensing arrangements or related revenues.
Halozyme has collaboration agreements with large pharma companies, like J&J (JNJ - Free Report) and argenx (ARGX - Free Report) , among others, which use its ENHANZE technology to develop SC formulations of their various approved drugs.
J&J uses the technology to administer the multiple myeloma therapy Darzalex (marketed as Darzalex Faspro/SC). On the other hand, argenx uses the same to deliver the generalized myasthenia gravis therapy Vyvgart, marketed as Vyvgart Hytrulo.
These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Image: Bigstock
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Key Takeaways
Halozyme Therapeutics (HALO - Free Report) announced that a German Higher Regional Court has overturned a preliminary injunction that had prohibited Merck (MRK - Free Report) from distributing and offering Keytruda’s subcutaneous (SC) formulation in Germany.
The latest development follows a December 2025 ruling by a German court that granted Halozyme a preliminary injunction against Merck, preventing the distribution and offering of Keytruda SC in Germany. However, the Higher Regional Court has now overturned that order.
Halozyme expressed disappointment with the latest decision, stating that it disagrees with the court's ruling. The company plans to immediately file a patent infringement lawsuit against Merck in Germany, seeking permanent relief. The latest decision does not prevent Halozyme from pursuing further legal action.
Shares of Halozyme were down 2.9% yesterday following the announcement of the news.
The stock has rallied 38.3% so far this year compared with the industry’s increase of 5.7%.
Image Source: Zacks Investment Research
HALO’s Previous Court Ruling
In October 2026, a Dutch patent court ruled in Halozyme's favor in another patent dispute involving Merck's Keytruda SC. The court prohibited Merck's European Marketing Authorization holder from manufacturing, offering, selling or using Keytruda SC in eight European countries: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands.
It also prevents Merck from allowing its affiliates to continue selling the drug in these markets, including through the use of its European marketing authorization.
Importantly, the German and Dutch proceedings are separate and independent. Therefore, the latest German ruling does not reverse the Dutch court's October 2026 decision.
What This Means for Halozyme
The legal dispute centers on Halozyme's MDASE patent portfolio, which covers technology designed to facilitate the rapid subcutaneous administration of therapeutic drugs using modified human hyaluronidases.
Halozyme noted that its MDASE patents are separate from its ENHANZE drug delivery technology patents and are not included in its ENHANZE licensing program. Consequently, the outcome of the MDASE patent enforcement proceedings against Merck is not expected to affect the company's ENHANZE licensing arrangements or related revenues.
Halozyme has collaboration agreements with large pharma companies, like J&J (JNJ - Free Report) and argenx (ARGX - Free Report) , among others, which use its ENHANZE technology to develop SC formulations of their various approved drugs.
J&J uses the technology to administer the multiple myeloma therapy Darzalex (marketed as Darzalex Faspro/SC). On the other hand, argenx uses the same to deliver the generalized myasthenia gravis therapy Vyvgart, marketed as Vyvgart Hytrulo.
These agreements generate royalties on sales of marketed drugs, milestone payments and annual license fees, which comprise Halozyme’s top line.
Halozyme Therapeutics, Inc. Price
Halozyme Therapeutics, Inc. price | Halozyme Therapeutics, Inc. Quote
HALO’s Zacks Rank
Halozyme currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.